Rheumatology International

, Volume 33, Issue 10, pp 2665–2670 | Cite as

Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients

  • Benigno Casanueva
  • Baltasar Rodero
  • Covadonga Quintial
  • Javier Llorca
  • Miguel A. González-GayEmail author
Short Communication


The purpose of this study was to evaluate the short-term efficacy of topical capsaicin treatment in patients severely affected by fibromyalgia. One hundred and thirty fibromyalgia patients were randomly divided into two groups. The control group, 56 women and 4 men who continued their medical treatment, and the capsaicin group, 70 women who apart from continuing their medical treatment, also underwent topical capsaicin 0.075 % 3 times daily for 6 weeks. At the beginning of the program, there were no significant differences between the two groups in any of the analyzed parameters. At the end of the treatment, there were significant improvements in the capsaicin group in the myalgic score (5.21 vs 3.8, p = 0.02) and global subjective improvement (22.8 vs 5 %, p = 0.001). Six weeks after the end of the treatment, the experimental group showed significant differences in Visual Analogue Scale of depression (5.63 vs 7.35, p = 0.02), Fibromyalgia Impact Questionnaire (67.89 vs 77.7, p = 0.02), role limitations due to emotional problems (36.17 vs 17.2, p = 0.05), Fatigue Severity Scale (6.2 vs 6.6, p = 0.04), myalgic score (3.94 vs 2.66, p = 0.02) and pressure pain threshold (79.25 vs 56.71, p = 0.004). In conclusion, patients severely affected by fibromyalgia can obtain short-term improvements following topical capsaicin 0.075 % treatment three times daily for 6 weeks.


Fibromyalgia Capsaicin therapy Chronic pain Clinical assessment 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of FM: report of the Multicenter Criteria Committee. Arthritis Rheum 33(2):160–172PubMedCrossRefGoogle Scholar
  2. 2.
    Staud R (2002) Evidence of involvement of central neural mechanisms in generating fibromyalgia pain (review). Curr Rheumatol Rep 4(4):299–305PubMedCrossRefGoogle Scholar
  3. 3.
    Herpfer I, Lieb K (2003) Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 4(2):56–63PubMedCrossRefGoogle Scholar
  4. 4.
    Russell IJ, Orr MD, Littman B et al (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37(11):1593–1601PubMedCrossRefGoogle Scholar
  5. 5.
    Nolano M, Simone DA, Wendelschafer-Crabb G et al (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain 81(1–2):135–145PubMedCrossRefGoogle Scholar
  6. 6.
    Morgenlander JC, Hurwitz BJ, Massey EW (1990) Capsaicin for the treatment of pain in Guillain-Barré syndrome. Ann Neurol 28(2):199PubMedCrossRefGoogle Scholar
  7. 7.
    Mason L, Moore RA, Derry S et al (2004) Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 328(7446):991PubMedCrossRefGoogle Scholar
  8. 8.
    Vargas A, Vargas A, Hernandez-Paz R et al (2006) Sphygmomanometry-evoked allodynia-a simple bedside test indicative of fibromyalgia: a multicentre developmental study. J Clin Rheumatol 12(6):272–274PubMedCrossRefGoogle Scholar
  9. 9.
    Lázaro C, Bosch F, Torrubia R et al (1994) The development of a Spanish questionnaire for assessing pain: preliminary data concerning reliability and validity. Eur J Psychol Assess 10(2):145–151Google Scholar
  10. 10.
    Tan G, Jensen MP, Thornby JI et al (2004) Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 5(2):133–137PubMedCrossRefGoogle Scholar
  11. 11.
    Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1124PubMedCrossRefGoogle Scholar
  12. 12.
    Royuela Rico A, Macías Fernández JA (1997) Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 9(2):81–94Google Scholar
  13. 13.
    Beck AT, Brown G, Epstein N et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 56:893–897CrossRefGoogle Scholar
  14. 14.
    Beck AT, Ward CH, Mendelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedCrossRefGoogle Scholar
  15. 15.
    García Campayo J, Rodero B, Alda M et al (2008) Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia. Med Clín 131(13):487–492CrossRefGoogle Scholar
  16. 16.
    Rivera J, Gonzalez T (2004) The Fibromyalgia impact questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22(5):554–560PubMedGoogle Scholar
  17. 17.
    Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1(1):20PubMedCrossRefGoogle Scholar
  18. 18.
    Harwood RH, Rogers A, Dickinson E et al (1994) Measuring handicap: the London handicap scale a new outcome measure for chronic disease. Qual Health Care 3(1):11–16PubMedCrossRefGoogle Scholar
  19. 19.
    Staud R (2010) Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Cur Rheumatol Rep 12(6):448–454CrossRefGoogle Scholar
  20. 20.
    Hong CZ, Hsueh TC (1996) Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 77(11):1161–1166PubMedCrossRefGoogle Scholar
  21. 21.
    Morris V, Cruwys S, Kidd B (1998) Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 250(3):205–207PubMedCrossRefGoogle Scholar
  22. 22.
    McCarty DJ, Csuka M, McCarthy G et al (1994) Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 23(Suppl 3):41–47CrossRefGoogle Scholar
  23. 23.
    Acasuso Diaz M, Collantes Estevez E, Jordi Reus S (1998) Capsaicina versus ketoprofen en tratamiento tópico de la fibromialgia primaria. XXIV Congreso Nacional de la Sociedad Española de Reumatología, Cádiz, JunioGoogle Scholar
  24. 24.
    Ebner K, Muigg P, Singewald G et al (2008) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann NY Acad Sci 1144:61–73PubMedCrossRefGoogle Scholar
  25. 25.
    Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 40(7):743–749CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Benigno Casanueva
    • 1
  • Baltasar Rodero
    • 2
  • Covadonga Quintial
    • 3
  • Javier Llorca
    • 4
  • Miguel A. González-Gay
    • 5
    Email author
  1. 1.Rheumatology Service at the Specialist Clinic of CantabriaSantanderSpain
  2. 2.Rodero CenterSantanderSpain
  3. 3.Neurophysiology ServiceSanta Clotilde HospitalSantanderSpain
  4. 4.Department of Epidemiology and Computational Biology, School of MedicineUniversity of Cantabria, IFIMAVSantanderSpain
  5. 5.Rheumatology ServiceHospital Universitario Marqués de Valdecilla. IFIMAVSantanderSpain

Personalised recommendations